Index

Page numbers in *italics* denote figures and tables.

ADHD See attention deficit hyperactivity disorder

American migraine prevalence and prevention (AMPP) study, 114

anxiety disorders

case report, 2, 129–30

children, 128

depression, 6–8

migraine patients, 3

‘syndromic relationship’, 128–9

atherosclerosis risk in communities

study, 16

attention deficit hyperactivity disorder (ADHD), 126

aura without headache, 72

autosomal dominant vascular retinopathy, 18

basilar-type migraine, 71–2

benign paroxysmal vertigo, 72

CADSIL, 18, 21

cardio- and cerebrovascular disorders

congenital heart defects, 123

diagnosis and management risk, 35–6

stroke/MI, 36

epidemiology

cardiovascular disease risk, 27–8

migraine and cardiovascular risk, 33–4

triptans and cardiovascular risk, 31–2

women's and physicians' health study, 29–31

Framingham-risk, 19, 34

ischemic stroke, 19

pathophysiology

endothelial dysfunction (ED), 34

endothelial progenitor cells (EPCs), 34–5

PFO, 123–4

central convergence theory, 86–8

childhood periodic syndromes, 72

children, migraine comorbidities

ADHD, 126–7

anxiety disorders, 128–9

asthma and allergic disorders, 123

cardiovascular disease, 123–4

case reports, 129–30

depression, 127–8

epilepsy and obesity, 125

Gilles de la Tourette syndrome, 127

learning disabilities, 126

medical and psychiatric, 122

pathophysiology, 122

sleep disorders

management, 126

stroke, 124

chronic daily headache

drugs, 102

MOH, 100, 106

obesity, 113–14

© 2011 Blackwell Publishing Ltd. Published 2011 by Blackwell Publishing Ltd.
prevalence, adolescents, 98
TMD symptoms, 117–18
cortical spreading depression (CSD),
18, 19, 46, 65
confusional migraine, 71–2
depression
antidepressants, 135
bipolar subtype, 2–3
SMILE study, 6–8
electroencephalogram (EEG)
migraine and epilepsy, diagnosis
aura, 69–70
ictus, 70
postdrome/post-ictal phase, 70
premonitory phase, 69
seizure-associated headache, 71
rhythmic seizure discharge, 60, 61
epilepsy
antiepileptic drugs (AEDs), 125
aura
definition, 69–70
description, 69
visual hallucinations, 70
case study, Marlie with MA
EEG, rhythmic seizure discharge,
59–61
treatment, 59
diagnosis and classification
children, 67
differential and concomitant,
EEG, 68–71
EEG, 71
ictal progression and symptoms,
67, 68
MA vs., 68
primary headaches, 66–7
seizures and epileptic
syndromes, 67
syndromes, 72–3
variants, 71–2
epidemiology
MA and MO, 63
prevalence, 62–3
ictus, headache/ seizure phase, 70
occurrence, 62
pathophysiology
risk factors, 64–6
unidirectional causal models, 63
postdrome/post-ictal phase, 70
post-ictal, 72
premonitory phase, 69
seizure-associated headache, 71
treatment
acute and preventive
modalities, 74
concomitant diagnoses, 73
tricyclic antidepressants and
neuroleptic drug, 73–4
Gastaut syndrome, 73
genetic epidemiology of migraine
(GEM) study, 33
genetic risk factors, migraine and
epilepsy
brain substrate
epileptogenesis, 64–5
seizures, 64
FHM genes
ATP1A2, 65–6
CACNA1A, 65
SCN1A, 66
Gilles de la Tourette syndrome, 127
headache terminators, 102, 104
International Classification of
Headache Disorders (ICHD-2)
confusional migraine, 71–2
migrainous infarction, 17
migralepsy, 72
International Headache Society (IHS),
96–7, 114
International League Against Epilepsy
(ILAE), 62, 67
intranasal contact points
headache frequency and scores,
119–20
mucosal contact headache, 119
learning disabilities (LD)
causes of, 126
prevalence, US children, 126
low-dose aspirin therapy, 21–2
MA See migraine with aura
medication overuse headache (MOH)
characteristics, 100
description, 96
diagnosis
ergot, 100–101
triptans, 101
epidemiology
medication overuse headache (cont’d)
analgesics, 97
drug-induced, 97–8
population-based studies, 98
primary headache, 98
IHS criteria, 97
management
detoxification, 102, 104
drug withdrawal, 103
episodic headache, 102
headache terminators, 104–5
hospitalization, 103–4
inpatient headache
treatment, 104
preventive treatment, 101
prophylactic drugs, 102
psychiatric illness, 101
symptoms, 102–3
topiramate, 101–2
occurrence, 96–7
pathophysiology
chronic daily headache
(CDH), 99
5-hydroxytryptamine (5-HT),
99–100
mammalian nervous system, 99
migraineurs, 98–9
non-migraineurs, 98
rostral ventromedial medulla
(RVM), 99
prevention, 105
prognosis
CDH, 106
withdrawal therapy, 105–6
methylenetetrahydrofolate reductase
enzyme (MTHFR C677T)
homocysteine, 20, 33
homozygosity and migraine, 33–4
replication, 34
migraine-epilepsy syndromes
benign rolandic epilepsy, 73
childhood benign partial, occipital
paroxysms
Gastaut, 73
Panayiotopoulos, 72–3
migraine-triggered seizure, 72
Migraine Intervention with STARFlex©
Technology (MIST) trial, 20
migraine with aura (MA)
CVD, 31
and epilepsy
comorbidity, 63
definition, 69–70
symptoms, 68
Framingham risk, 34
ischemic stroke, 15–17
mechanism, 27
women, 19
and MO, 50
MTHFR C677T, 20
myocardial infarction and
cardiovascular death, 18–19
PFO, 123–4
visual hallucinations, 70
migraine without aura (MO)
case report, 1–2
ischemic stroke, 15
and MA, 50
PFO, 45
mitochondrial myopathy,
encephalopathy, lactacidosis
and stroke (MELAS), 18
MO See migraine without aura
MOH See medication overuse
headache
N-methyl-D-aspartate receptors
(NMDAR), 99
obesity
AMPP study, 114–15
BMI, episodic and chronic
migraine, 113, 114
CDH, 113–14
children, 125
clinical intervention, 116
and migraine population studies, 115
weight change, 115–16
pain disorders and migraine
case presentation
history, 81
primary comorbidity, 82
prophylactic medication, 82
treatment, 81–2
comorbidity, 83
diagnosis and patient handling
musculoskeletal system, 91–2
primary and secondary
headache, 91
prophylactic drugs, 92
headaches, comorbidity
adults, 85
children, 84
migraine with aura, 19
MIST trials, 20
recommendations, migraine
patient, 51
pathophysiology, migraine and stroke
cardiovascular risk factors
with aura, 18–19
ischemic stroke, 19
myocardial infarction, 18
RR, 19
cerebral ischemia, 18
distinct disorders, 18
genetic polymorphisms, 20
ischemic vascular events, 17–18
migrainous infarction, 17
PFO (see patent foramen ovale)
postmenopausal hormone
replacement, 18
treatments
ergots use, 20
triptan therapy, 20–21
peripheral triggering theory, 86
PFO See patent foramen ovale
probable migraine with visual aura
(PMVA), 124
psychiatric comorbidity
affective disorders
depression, 2
mood, 2–3
symptoms, 3
anxiety disorders
and depression, 3
panic attacks, 3
perfectionism and
obsessionality, 3
case report
acute antimigraine drugs, 2
anxiety, 1–2
hypersomnia, abulia and
anhedonia, 2
medication overuse headache
(MOH), 1
treatment approach, 10
impact
acute antimigraine
medications, 8
anxiety and depression, 8
disability, 6, 8
FRAMIG study, 6–7
SMILE, 7
management
antiepileptic drugs, 9
psychiatric comorbidity (cont’d)
behavioral treatments, 9
depression and anxiety, 8
drugs, 8–9
monoamine oxidase inhibitors
(MAOIs), 9
preventive therapy, 132
tricyclic antidepressants, 9
mechanisms
anxiety disorders, 5
factors, 4
and headache frequency, 5–6
monoamine systems/
channelopathies, 6
substance dependence
MOH, 4
nicotine, alcohol and illicit drugs,
3–4
painkillers and barbiturates, 4
Raynaud phenomenon, 18
relaxation therapy, 10, 104
sleep disorders, 125–6
stroke and migraine
brain cells and artery dysfunction, 14
diagnosis, 21
epidemiology
atherosclerosis risk in
communities study, 16
diagnoses, 16–17
hemorrhagic and ischemic
stroke, 17
ischemic, risk, 15
migraineurs, aura, 15–16
stroke prevention in young
women study, 16
management
aura features, 22
low-dose aspirin therapy, 21–2
traditional risk factors, 21
pathophysiology
cardiovascular risk factors, 18–19
cerebral ischemia, 18
distinct disorders, 18
 genetic polymorphisms, 20
ischemic vascular events, 17–18
migrainous infarction, 17
PFO (see patent foramen ovale)
postmenopausal hormone
replacement, 18
treatments, 20–21
probable migraine with visual aura
(PMVA), 124
stroke prevention in young women
study, 16
temporomandibular disorders (TMD)
characterization, 117
description, 116
and migraine
comorbidity, 117
influence, 117–18
treatment of, 118–19
unidirectional causal models, 63
withdrawal therapy, 103, 106